Privately-held NormOxys Raises $17.5 Million Series B To Further Develop Its Novel "Oxyren" Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The money, provided by returning backer Index Ventures and new investor Care Capital, will support clinical development of NormOxys' lead drug candidate through proof-of-concept testing.
You may also be interested in...
Risks Of Blood Substitute Drugs Merit Return To Toxicology Studies – JAMA
The toxicities of developmental hemoglobin-based oxygen carriers must be defined in preclinical animal testing replicating the products' known toxicities in humans before further humans trials are allowed to proceed, the authors of a study published April 28 in the Journal of the American Medical Association argue
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.